WHO ICTRP trial
A phase IA/II, multi-center, open-label study of HCD122 administered…
EUCTR2007-004888-22-BE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2007-004888-22-BE |
|---|---|
| Public title | A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies - CHCD122A2103 |
| Scientific title | A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies - CHCD122A2103 |
| Primary sponsor | Novartis Pharma AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;Belgium;Germany;United Kingdom |
| Conditions | Advanced non Hodgkin's or Hodgkin's lymphoma |
| Interventions | Product Name: HCD122 Product Code: HCD122 Pharmaceutical Form: Solution for infusion Current Sponsor code: HCD122 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100/5- |
| Registration date | Dec 2, 2008 |
| Target size | 230 |
| Secondary IDs | CHCD122A2103 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: